Monographie - Dactinomycin

Poslední aktualizace :
08/05/2024

Dactinomycin

Cheminė sandara

Prekinis pavadinimas

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cosmegen	Argentina, Australija, Austrija, Graikija, Iranas, Italija, Jungtinės Amerikos Valstijos, Kanada, Malaizija, Meksikas, Naujojoje Zelandijoje, Norvegija, Prancūzija, Suomija, Švedija, Šveicarija
Cosmegen Lyovac	Airija, Didžioji Britanija, Rumunija
Dacilon	Čilė, Indija, Peru
Dacmozen	Indija
Dactino	Indija
Dactinomicina	Čilė, Ekvadoras, Kolumbija, Peru
Dactinomycin	Naujojoje Zelandijoje
Lyovac Cosmegen	Belgija, Liuksemburgas, Olandija, Vokietija

Bibliografija : Dactinomycin

	Tipas	Leidinys
3	Žurnalas	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
84	Žurnalas	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Žurnalas	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Žurnalas	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Žurnalas	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Žurnalas	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Žurnalas	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Žurnalas	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Žurnalas	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Žurnalas	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Žurnalas	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
729	Žurnalas	Rusmin S, Welton S, DeLuca P, DeLuca PP. Effect of inline filtration on the potency of drugs administered intravenously. Am J Hosp Pharm 1977 ; 34: 1071-1074.
857	Žurnalas	Kanke M, Eubanks JL, DeLuca PP. Binding of selected drugs to a “treated” inline filter. Am J Hosp Pharm 1983 ; 40: 1323-1328.
905	Žurnalas	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1178	Žurnalas	Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981 ; 38: 1914-1918.
1322	Žurnalas	Ennis CE, Merritt RJ, Neff DN. In vitro study of inline filtration of medications commonly administered to pediatric cancer patients. JPEN 1983 ; 7: 156-158.
1410	Žurnalas	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Žurnalas	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
4153	Laboratorija	Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics Orphan Europe (UF) Limited 2014

Mentions Légales